ClinicalTrials.gg
CompletedNCT06695988Updated Oct 19, 2026

Time-restricted Eating Acceptability, Efficacy and Safety in Obesity

An interventional study of Time Restricted Eating in Time Restricted Eating and Obesity, sponsored by University of Mississippi, Oxford. Completed at 1 site in United States. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by University of Mississippi, Oxford · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2024, registered Nov 2024).
Updated Oct 19, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 113 studies in Intermittent Fasting with a site in United States — 33 open to participants now, 44 under way, none of them phase 3. Intermittent Fasting · United States.

Enrollment
52nd of 112
44 · median 40
Started
2024
with 15 others
No phase
104 of 113
26 open now
Registered
89th of 113
by date

Among the 113 studies in Intermittent Fasting with a site in United States, this one is the 52nd largest by enrollment of the 112 interventional ones that give a count, is one of 16 that started in 2024, is one of 104 with no phase, and was the 89th registered.

Intermittent Fasting

334 studies on the registry are indexed under Intermittent Fasting; 100 are open to participants now.

Browse Intermittent Fasting studies →

Open to participants now

33 of the 113 studies in Intermittent Fasting with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 74 Intermittent Fasting studies recruiting now, 19 (26%) set no upper age limit and 49 (66%) stop at 75 or younger; 4 take children under 18; 22 take healthy volunteers.

This study: 19 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Intermittent Fasting with a site in United States, or all of them as a file.
02

Study summary

A randomized controlled trial to determine adherence, acceptability and safety of time restricted eating (TRE) in healthy, sedentary, free-living adults with obesity between the ages of 19-65 years when following 16:8 TRE for 8 weeks. This 9-week study includes a baseline week and 8 weeks of the intervention period. Participants are randomly assigned to the TRE or the non-fasting control group. The TRE group will consume calorie containing food and drink only over an 8 hour period and rest of the 16 hour would be fasting. Adherence to TRE and calorie intake are the primary outcomes. Motivators, facilitators and barriers to TRE, hunger and cravings levels, weight bias internalization, body composition (weight, body fat%, fat mass and muscle mass) , Healthy Eating Index (HEI) to assess diet quality, skin carotenoid levels, disordered eating risk, sleep quality, and perceptions of health and well-being are secondary outcomes.

03

Conditions studied

  • Time Restricted Eating
  • Obesity

Keywords

  • Time Restricted Eating
  • Obesity
  • Intervention
  • 9 weeks
  • Randomization
  • Intermittent fasting
04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 19 to 65 years
  • Owns a smartphone
  • Apparently healthy
  • ( more than or equal to 25 kg/m2 ) and high body fat percent (BF%) (≥25% and ≥35% for males and females, respectively)
  • Sedentary lifestyle (less than 150 minutes of self-reported moderate to vigorous activity per week)
  • Self-reported eating interval of ≥12 h per day

Exclusion criteria

Exclusion Criteria:

  • Diagnosed diabetes mellitus (type I or II), coronary heart disease, heart failure, hypertension, hyperlipidemia, stroke, chronic lung diseases, liver or kidney disease, adrenal diseases, musculoskeletal disorders, uncontrolled thyroid disease (dose changes within the past 3 months), Crohn's disease, Ulcerative Colitis, arthritis, undergoing active cancer treatment except for non-melanoma cancer, uncontrolled psychiatric disorder (a history of hospitalization for psychiatric illness).
  • Currently taking any medication that is meant for, or has a known effect on, appetite
  • On anabolic steroid or hormone replacement therapy
  • Participation in an exercise/nutrition/ weight-loss program within the last 6 months
  • Any history of surgical intervention for weight management
  • Having a ≥5% body weight change during the last 3 months
  • Pregnant or less than 6 months post-partum, breastfeeding, polycystic ovarian syndrome or irregular menstruation
  • missing limbs, have a pacemaker or metal implants,
  • eating disorders or EAT-26 score >20
  • Alcohol or drug addiction
  • Current smoker
  • Works night shifts
  • Unable to commit to a 9-week study
  • Not willing to follow study protocol and any other .
  • Currently following any of the following restrictive diets - Keto/low carbohydrate/ Vegan/ Vegetarian/ Intermittent fasting/ Paleo/ Calorie restriction/ Any other restrictive diet
  • Participating in another study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Time Restricted Eating Group

    The TRE group will consume calorie-containing food and drinks only over an 8-hour window between 6 a.m. to 8 p.m. for 8 weeks. During the fasting period, they can take only calorie-free fluids.

    Behavioral: Time Restricted Eating

  • No intervention
    Control

    They will follow their usual eating patterns and consume food over a period of 12 hours or more.

Interventions

  • BehavioralTime Restricted Eating

    The intervention group will eat and drink in a prescribed daily feeding window of 8-hour between 6 a.m. to 8 p.m. for 8 weeks and follow their normal exercise and resistance training routines. We will allow +/-1 hour starting and ending times for the eating window while aiming for an 8-hour eating window

06

What researchers measure

Primary outcomes

  1. Adherence

    Percent of days during the 8-week trial when TRE was adhered to as recommended. This will be self-reported daily.

    Time frame: 8 weeks

  2. Total calorie intake

    Pre and post intervention measurements of calorie intake based on three 24-hour food recall surveys using the NDSR software.

    Time frame: During baseline week and week 8 of the intervention

Secondary outcomes

  1. Body weight (kg)

    Pre and post intervention measures of body weight.

    Time frame: At baseline and at the end of 8 weeks of intervention

  2. 24-hour physical activity energy expenditure (PAEE)

    GT9X Actigraph accelerometer will be used over 7 days to measure physical activity energy expenditure pre-intervention and during week 8 of the intervention.

    Time frame: During baseline week and week 8 of the intervention

  3. Body fat percentage (%)

    Pre and post intervention measurements of body fat percentage measured by bioelectrical impedance analyzer.

    Time frame: At baseline and at the end of 8 weeks of intervention

  4. Fat-free mass (kg)

    Pre and post intervention measurements of body fat-free mass (kg) measured by bioelectrical impedance analyzer.

    Time frame: At baseline and at the end of 8 weeks of intervention

  5. Fat mass (kg)

    Pre and post intervention measurements of body fat mass (kg) measured by bioelectrical impedance analyzer.

    Time frame: At baseline and at the end of 8 weeks of intervention

  6. Hunger and satiety

    Pre and post intervention subjective measure of hunger and satiety with the use of a Hunger and Satiety Visual Analog Scale

    Time frame: During baseline week and week 8 of the intervention

  7. Sleep quality

    Pre and post intervention measure of subjective sleep quality by use of Pittsburgh Sleep Quality Scale.

    Time frame: One time during the baseline week and week 8 of the intervention

  8. Diet Quality

    Pre and post intervention measurements of diet quality based on three 24-hour food recall surveys at pre- and post collected using the NDSR software and Healthy Eating Index was calculated.

    Time frame: During baseline week and week 8 of the intervention

  9. Perceptions of health and well-being

    Pre- and post quality of life will be assessed using RAND 36-Item Health Survey 1.0 (SF-36)

    Time frame: At baseline and at the end of 8 weeks of intervention

  10. Weight Bias Internalization

    Pre- and post weight bias internalization will be assessed using the Weight Bias Internalization Scale (WBIS).

    Time frame: At baseline and at the end of 8 weeks of intervention

  11. Disordered eating risk

    Pre- and post disordered eating risk will be assessed using Eating Attitude Test (EAT-26) survey scores

    Time frame: At baseline and at the end of 8 weeks of intervention

  12. Eating Behavior

    Pre and post eating behavior will be assessed using the Three Factor Eating Questionnaire (TFEQ-18). The TFEQ-R18 measures 3 aspects of eating behavior: cognitive restraint, uncontrolled eating, and emotional eating

    Time frame: At baseline and at the end of 8 weeks of intervention

  13. Skin carotenoid

    Pre- and post skin carotenoid levels will be measured pre and post-intervention using a non-invasive NuSkin Biophotonic scanner which is based on the Resonant Raman Spectroscopy technology.

    Time frame: At baseline and at the end of 8 weeks of intervention

  14. Motivators, barriers, and facilitators for following time restricted eating

    Motivators, barriers, and facilitators when following time restricted eating will be assessed only in the TRE group. These will be collected as qualitative data in the format of a semi-structured interviews over Zoom.

    Time frame: At end of 2nd week and during the 8th week of intervention.

07

Study locations

1 site
  • Department of Nutrition and Hospitality Management, University of Mississippi
    Oxford, Mississippi 38677, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Aug 2025, 14 months.

Of 259 non-industry interventional studies with no phase under Intermittent Fasting, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's 14 months is below that.

Counting every sponsor, half of 265 studies reached it within 17 months; a quarter within 8 and three quarters within 34.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2025 → Aug 2025, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2024
First posted
Nov 19, 2024
StartActual
Jun 18, 2024
Primary completionActual
Aug 28, 2025
CompletionActual
Aug 28, 2025was Oct 2025
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 19, 2026
Start date
Jun 1, 2024→Jun 18, 2024
Oct 19, 2026
Primary completion
Aug 31, 2025→Aug 28, 2025 (actual)
Oct 19, 2026
Study completion
Oct 31, 2025→Aug 28, 2025 (actual)
Oct 19, 2026
Enrollment
46 (estimated)→44 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Recruiting→Completed
    Start date Jun 1, 2024→Jun 18, 2024
    Primary completion Aug 31, 2025→Aug 28, 2025 (now actual)
    Study completion Oct 31, 2025→Aug 28, 2025 (now actual)
    Enrollment 46 (estimated)→44 (actual)
    + 8 other changes: index terms, identifiers, verification date, responsible party, conditions, contact details, site details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06695988
Lead sponsor
University of Mississippi, Oxford
Responsible party
Nadeeja Wijayatunga (Associate Professor, University of Mississippi, Oxford) — Principal investigator
First posted
Nov 19, 2024
Start date
Jun 18, 2024
Primary completion
Aug 28, 2025
Completion
Aug 28, 2025
Last update
Oct 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion